Surgery – Radioactive substance applied to body for therapy – Radioactive substance placed within body
Reexamination Certificate
1999-12-27
2001-10-23
Millin, Vincent (Department: 2164)
Surgery
Radioactive substance applied to body for therapy
Radioactive substance placed within body
C606S108000, C600S001000
Reexamination Certificate
active
06306073
ABSTRACT:
Within this application several publications are referenced by Arabic numerals within parentheses. Full citations for these references may be found at the end of the specification immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.
BACKGROUND OF THE INVENTION
The present invention relates to an apparatus and a method to treat a disease process in a luminal structure. Such a structure includes, but is not limited to, a vein, artery, bypass graft prosthesis, the gastrointestinal (GI) tract, the biliary tract, the genitourinary (GU) tract, and the respiratory tract (e.g. the tracheobronchial tree).
Percutaneous transluminal coronary angioplasty (PTCA) is commonly used in the treatment of coronary artezy obstruction, with over 400,000 procedures performed annually. PTCA is one of the most common current therapies for obstructive coronary artery disease (1). Unfortunately, it remains limited by a 30%-50% restenosis rate (2-5). The PTCA process involves the insertion of balloon catheters through the femoral artery to the targeted coronary artery. Injection of radio-opaque contrast into the proximal coronary artery allows fluoroscopic localization of stenosed coronary segments. Balloon catheters are advanced to the site of stenosis over extremely thin guide wires to position the catheter at the point of occlusion. The distal end of the catheter contains a balloon which is inflated for 2-4 minutes to the full diameter of the occluded artery, decreasing the blockage and improving blood flow.
In a related area, brachytherapy involves the implantation of a radioactive source within tissue t:o deliver localized radiation and is frequently applied to treat recurrent disease in an area previously treated by external beam radiation. Blind-end catheters may be used to deliver radiation to tumors in the esophagus, trachea, or rectum, for example. Advantages include the sparing of critical structures close to the tumor, and brevity of treatment (hours to days). Difficulties primarily involve anatomic constrains on implant placement. Comrion applications include the endoluminal treatment of recurrent endobronchial and bile duct tumors, the intracavitary treatment of cervical and endometrial cancer, and interstitial implants in unrespectable tumors with catheters or radioactive seeds.
As stated above, restenosis after arterial intervention in general, PTCA in particular, seem to be primarily due to medial smooth muscle cell proliferation. Conventional PTCA is performed using a balloon catheter such an over-the-wire type catheter manufactured, for example, by Scimed Life Systems, Inc, of Maple Grove, Minn. or a mono-rail type catheter manufactured, for example, by Advanced Cardiovascular Systems, Inc, of Temecula, Calif.
FIG. 1
depicts such a conventional over-the-wire balloon catheter
1
. The conventional balloon catheter
1
is utilized in an angioplasty procedure as follows. A conventional guidewire
2
is inserted into the patient's artery until the distal end of the guidewire
2
is past a target area (not shown) of the artery (not shown) where there is a buildup of material. The conventional balloon catheter
1
has a lumen
3
running therethrough. The guidewire
2
is inserted into the distal end of the balloon catheter
1
and the balloon catheter
1
is advanced over the guidewire until the balloon section
1
a
of the balloon catheter
1
is adjacent the buildup of material. The balloon section
1
a
is then inflated by an inflation means (not show) connected to an inflation port
1
b
to clear the artery. Finally, the balloon section
1
a
is deflated, the balloon catheter
1
is pulled back up the guidewire and removed and the guidewire is likewise removed from the patient's artery.
The main concern associated with using balloon catheters is the possibility of balloon failure or rupture, and the resulting biological and radiological toxicity.
Approximately 40% of patients undergoing this procedure have angiographic evidence of restenosis by 12 months. The mechanism of the restenosis process is not well understood, but both animal and human data suggest that it involves smooth muscle cell migration, proliferation, and neointima formation (
6
-
9
). Restenosis after stent implantation occurs at a somewhat lower rate of about 20%. Efforts to prevent restenosis using a variety of pharmacological or mechanical interventions or both have been largely unsuccessful in human and porcine models (
10
-
19
)
Although coronary artery blockage is a non-malignant disease, it has been suggested that treatment of the internal vessel walls with ionizing radiation could inhibit cell growth, and delay or even prevent restenosis (
24
,
36
-
40
). There exists a long and extensive experience with the use of ionizing radiation to treat non-malignant disease such as aneurysmal bone cysts, arteriovenous malformations, arthritis, chondroma, heterotopic bone formation, total lymphoid irradiation (for renal and heart transplantation) and pterygium (reviewed in
28
). Although this suggests that ionizing irradiation can be used to treat non-malignant, proliferative disorders, delivering such irradiation while minimizing damage to surrounding tissue has been a problem. And, in the case of balloon catheters, a continuous safety concern has been the rupture of the balloon and release of radioactive material into the bloodstream.
Details on catheters and their use can be found in U.S. Pat. Nos. 5,059,166, 5,213,561, 5,503,613, and PCT International Publication WO 95/19807. The disclosures of these documents in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.
SUMMARY OF THE INVENTION
The present invention provides a method of inhibiting a disease process in a luminal structure of a subject comprising introducing within the luminal structure a complex of a radionuclide and a chelating agent in an amount effective to inhibit the disease process.
This invention also provides an apparatus for treating a disease process in a luminal structure of a subject comprising a balloon catheter with a fluid delivery port connected thereto, and a radioactive fluid inserted into the balloon catheter through the fluid delivery port, said radioactive fluid comprising a complex of a radionuclide and a chelating agent in an amount effective to inhibit the disease process.
This invention further provides a method of treating a disease process in a luminal structure of a subject comprising introducing within the luminal structure the apparatus comprising a balloon catheter with a fluid delivery port connected thereto; and a radioactive fluid inserted into the balloon catheter through the fluid delivery port, said radioactive fluid comprising a complex of a radionuclide and a chelating agent in an amount effective to inhibit the disease process.
REFERENCES:
patent: 4454106 (1984-06-01), Gansow
patent: 4824659 (1989-04-01), Hawthorne
patent: 4889707 (1989-12-01), Day
patent: 4897076 (1990-01-01), Puthawala
patent: 5061476 (1991-10-01), Simon
patent: 5199939 (1993-04-01), Dake
patent: 5213561 (1993-05-01), Weinstein
patent: 5245018 (1993-09-01), Kondo
patent: 5300281 (1994-04-01), McMillan
patent: 5302168 (1994-04-01), Hess
patent: 5320824 (1994-06-01), Brodack
patent: 5411466 (1995-05-01), Hess
patent: 5436352 (1995-07-01), Srinivasan
patent: 5503613 (1996-04-01), Weinberger
patent: 5556389 (1996-09-01), Liprie
patent: 5575815 (1996-11-01), Slepian
patent: 5616114 (1997-04-01), Thorton
patent: 5924973 (1999-07-01), Weinberger
patent: 747069 (1996-12-01), None
patent: 9304735 (1993-03-01), None
patent: 9211932 (1995-07-01), None
patent: 9519807 (1995-07-01), None
patent: 9719723 (1997-06-01), None
patent: 9738730 (1997-10-01), None
patent: 9748452 (1997-12-01), None
patent: 9848851 (1998-11-01), None
patent: 9902194 (1999-01-01), No
Cooper & Dunham LLP
Millin Vincent
O'Hara Kelly
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
Apparatus and method for treating a disease process in a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Apparatus and method for treating a disease process in a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Apparatus and method for treating a disease process in a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2576281